BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America

09 6月 2022 06:00:00 条件 Nasdaq GlobeNewswire

FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250

08 6月 2022 06:00:01 条件 Nasdaq GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic

07 6月 2022 08:00:02 条件 Nasdaq GlobeNewswire

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

06 6月 2022 06:00:30 条件 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

01 6月 2022 06:00:15 条件 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

06 5月 2022 06:00:28 条件 Nasdaq GlobeNewswire

BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones

05 5月 2022 06:00:11 条件 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 5月 2022 15:15:39 条件 Nasdaq GlobeNewswire

European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

27 4月 2022 06:00:00 条件 Nasdaq GlobeNewswire

BioCryst to Report First Quarter 2022 Financial Results on May 5

21 4月 2022 06:00:52 条件 Nasdaq GlobeNewswire